JP2010531878A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010531878A5 JP2010531878A5 JP2010514839A JP2010514839A JP2010531878A5 JP 2010531878 A5 JP2010531878 A5 JP 2010531878A5 JP 2010514839 A JP2010514839 A JP 2010514839A JP 2010514839 A JP2010514839 A JP 2010514839A JP 2010531878 A5 JP2010531878 A5 JP 2010531878A5
- Authority
- JP
- Japan
- Prior art keywords
- human
- pharmaceutical composition
- derivative
- cancer cells
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US93747107P | 2007-06-27 | 2007-06-27 | |
| PCT/US2008/008084 WO2009002562A2 (en) | 2007-06-27 | 2008-06-27 | Complexes of il-15 and il-15ralpha and uses thereof |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014001373A Division JP2014114294A (ja) | 2007-06-27 | 2014-01-08 | ＩＬ‐１５とＩＬ‐１５Ｒαとの複合体及びその使用 |
| JP2015115431A Division JP2015212270A (ja) | 2007-06-27 | 2015-06-08 | ＩＬ‐１５とＩＬ‐１５Ｒαとの複合体及びその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010531878A JP2010531878A (ja) | 2010-09-30 |
| JP2010531878A5 true JP2010531878A5 (enExample) | 2011-08-11 |
Family
ID=40186225
Family Applications (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010514839A Pending JP2010531878A (ja) | 2007-06-27 | 2008-06-27 | ＩＬ‐１５とＩＬ‐１５Ｒαとの複合体及びその使用 |
| JP2014001373A Pending JP2014114294A (ja) | 2007-06-27 | 2014-01-08 | ＩＬ‐１５とＩＬ‐１５Ｒαとの複合体及びその使用 |
| JP2015115431A Pending JP2015212270A (ja) | 2007-06-27 | 2015-06-08 | ＩＬ‐１５とＩＬ‐１５Ｒαとの複合体及びその使用 |
| JP2016226503A Withdrawn JP2017079745A (ja) | 2007-06-27 | 2016-11-22 | ＩＬ‐１５とＩＬ‐１５Ｒαとの複合体及びその使用 |
| JP2018245439A Withdrawn JP2019088288A (ja) | 2007-06-27 | 2018-12-27 | ＩＬ‐１５とＩＬ‐１５Ｒαとの複合体及びその使用 |
| JP2021086283A Pending JP2021152017A (ja) | 2007-06-27 | 2021-05-21 | ＩＬ‐１５とＩＬ‐１５Ｒαとの複合体及びその使用 |
| JP2022172896A Pending JP2023015158A (ja) | 2007-06-27 | 2022-10-28 | ＩＬ‐１５とＩＬ‐１５Ｒαとの複合体及びその使用 |
Family Applications After (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014001373A Pending JP2014114294A (ja) | 2007-06-27 | 2014-01-08 | ＩＬ‐１５とＩＬ‐１５Ｒαとの複合体及びその使用 |
| JP2015115431A Pending JP2015212270A (ja) | 2007-06-27 | 2015-06-08 | ＩＬ‐１５とＩＬ‐１５Ｒαとの複合体及びその使用 |
| JP2016226503A Withdrawn JP2017079745A (ja) | 2007-06-27 | 2016-11-22 | ＩＬ‐１５とＩＬ‐１５Ｒαとの複合体及びその使用 |
| JP2018245439A Withdrawn JP2019088288A (ja) | 2007-06-27 | 2018-12-27 | ＩＬ‐１５とＩＬ‐１５Ｒαとの複合体及びその使用 |
| JP2021086283A Pending JP2021152017A (ja) | 2007-06-27 | 2021-05-21 | ＩＬ‐１５とＩＬ‐１５Ｒαとの複合体及びその使用 |
| JP2022172896A Pending JP2023015158A (ja) | 2007-06-27 | 2022-10-28 | ＩＬ‐１５とＩＬ‐１５Ｒαとの複合体及びその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US9931377B2 (enExample) |
| EP (3) | EP2173378B1 (enExample) |
| JP (7) | JP2010531878A (enExample) |
| AU (1) | AU2008269032B2 (enExample) |
| CA (1) | CA2691785C (enExample) |
| DK (1) | DK2173378T3 (enExample) |
| ES (2) | ES2466916T3 (enExample) |
| HK (1) | HK1198421A1 (enExample) |
| IL (1) | IL202997A (enExample) |
| NZ (4) | NZ616254A (enExample) |
| WO (1) | WO2009002562A2 (enExample) |
Families Citing this family (118)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007001677A2 (en) | 2005-05-17 | 2007-01-04 | University Of Connecticut | Compositions and methods for immunomodulation in an organism |
| EP1777294A1 (en) | 2005-10-20 | 2007-04-25 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins |
| JP5603012B2 (ja) | 2005-12-02 | 2014-10-08 | トヘ モウント シナイ スクール オフ メディシネ オフ ニューヨーク ウニベルシトイ | 非天然表面タンパク質を提示するキメラウイルス及びその使用 |
| EP2366787B1 (en) | 2006-01-13 | 2019-12-11 | The Government Of The U.S.A, As Represented By The Secretary, Dept. Of Health And Human Services | Codon optimized IL-15 and IL-15R-Alpha genes for expression in mammalian cells |
| EP2388266B1 (en) | 2007-05-11 | 2014-04-23 | Altor BioScience Corporation | Fusion molecules and IL-15 variants |
| EP2173378B1 (en) * | 2007-06-27 | 2014-03-19 | Admune Therapeutics LLC | Complexes of il-15 and il-15ralpha and uses thereof |
| WO2011020047A1 (en) | 2009-08-14 | 2011-02-17 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Use of il-15 to increase thymic output and to treat lymphopenia |
| KR20120093163A (ko) * | 2009-09-14 | 2012-08-22 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | Ｉｌ-15 수용체 알파 및/또는 이를 인코딩하는 핵산 분자를 포함하는 백신 및 면역 치료제, 및 이를 이용하는 방법 |
| CN101837123B (zh) * | 2010-05-27 | 2016-05-25 | 四川大学 | 肿瘤细胞疫苗及其制备方法 |
| US11053299B2 (en) | 2010-09-21 | 2021-07-06 | Immunity Bio, Inc. | Superkine |
| JP6251570B2 (ja) | 2010-09-21 | 2017-12-20 | アルター・バイオサイエンス・コーポレーション | 多量体ｉｌ−１５可溶性融合分子並びにその製造及び使用方法 |
| AU2011317211B2 (en) | 2010-10-22 | 2015-04-16 | Dana-Farber Cancer Institute, Inc. | Discovery of regulatory T cells programmed to suppress an immune response |
| EP2537933A1 (en) | 2011-06-24 | 2012-12-26 | Institut National de la Santé et de la Recherche Médicale (INSERM) | An IL-15 and IL-15Ralpha sushi domain based immunocytokines |
| US9156897B2 (en) * | 2012-06-08 | 2015-10-13 | Alkermes, Inc. | Fusion polypeptides comprising an active protein linked to a mucin-domain polypeptide |
| US10548957B2 (en) | 2012-09-28 | 2020-02-04 | Dana-Farber Cancer Institute, Inc. | Targeted expansion of Qa-1-peptide-specific regulatory CD8 T cells to ameliorate arthritis |
| US20150359853A1 (en) * | 2012-10-24 | 2015-12-17 | Admune Therapeutics Llc | Il-15r alpha forms, cells expressing il-15r alpha forms, and therapeutic uses of il-15r alpha and il-15/il-15r alpha complexes |
| PE20151921A1 (es) | 2013-03-14 | 2015-12-26 | Icahn School Med Mount Sinai | Virus de la enfermedad de newcastle y usos de los mismos |
| UY35468A (es) | 2013-03-16 | 2014-10-31 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19 |
| JP2016518361A (ja) | 2013-04-19 | 2016-06-23 | シーチューヌ ファルマＣｙｔｕｎｅ Ｐｈａｒｍａ | 血管漏出症候群の発生を抑制するサイトカイン治療 |
| EP2997134B1 (en) * | 2013-05-14 | 2020-06-24 | Board of Regents, The University of Texas System | Human application of engineered chimeric antigen receptor (car) t-cells |
| CA2920539C (en) * | 2013-08-08 | 2024-01-02 | Cytune Pharma | Combined pharmaceutical composition |
| SI3030575T1 (sl) | 2013-08-08 | 2018-11-30 | Cytune Pharma | Modulokini na osnovi IL-15 in IL-15R-alfa sushi domene |
| EP3093295B1 (en) | 2014-01-08 | 2020-05-27 | Shanghai Hengrui Pharmaceutical Co., Ltd. | Il-15 heterogeneous dimer protein and uses thereof |
| DK3105335T3 (da) | 2014-02-14 | 2020-01-13 | Univ Texas | Kimære antigenreceptorer og fremgangsmåder til fremstilling heraf |
| AU2015222685A1 (en) | 2014-02-27 | 2016-09-08 | Viralytics Limited | Combination method for treatment of cancer |
| EP2915569A1 (en) | 2014-03-03 | 2015-09-09 | Cytune Pharma | IL-15/IL-15Ralpha based conjugates purification method |
| CN122399016A (zh) | 2014-03-15 | 2026-07-17 | 诺华股份有限公司 | 使用嵌合抗原受体治疗癌症 |
| SG10202109752XA (en) | 2014-04-07 | 2021-10-28 | Novartis Ag | Treatment of cancer using anti-cd19 chimeric antigen receptor |
| CA2953816C (en) | 2014-06-30 | 2022-03-15 | Altor Bioscience Corporation | Il-15-based molecules and methods of use thereof |
| JP6831777B2 (ja) | 2014-07-21 | 2021-02-17 | ノバルティス アーゲー | Ｃｄ３３キメラ抗原受容体を使用する癌の処置 |
| AU2015292744C1 (en) | 2014-07-21 | 2021-01-21 | Novartis Ag | Treatment of cancer using humanized anti-BCMA chimeric antigen receptor |
| EP3180359A1 (en) | 2014-08-14 | 2017-06-21 | Novartis AG | Treatment of cancer using gfr alpha-4 chimeric antigen receptor |
| EP3712171A1 (en) | 2014-08-19 | 2020-09-23 | Novartis AG | Treatment of cancer using a cd123 chimeric antigen receptor |
| US10577417B2 (en) | 2014-09-17 | 2020-03-03 | Novartis Ag | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
| MA41044A (fr) | 2014-10-08 | 2017-08-15 | Novartis Ag | Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer |
| SG11201702401RA (en) | 2014-10-14 | 2017-04-27 | Novartis Ag | Antibody molecules to pd-l1 and uses thereof |
| US20180334490A1 (en) | 2014-12-03 | 2018-11-22 | Qilong H. Wu | Methods for b cell preconditioning in car therapy |
| US10905743B2 (en) * | 2014-12-19 | 2021-02-02 | Jiangsu Hengrui Medicine Co., Ltd. | Interleukin 15 protein complex |
| PL3280729T3 (pl) | 2015-04-08 | 2022-08-22 | Novartis Ag | Terapie cd20, terapie cd22 i terapie skojarzone komórką eksprymującą chimeryczny receptor antygenowy (car) cd19 |
| WO2016172583A1 (en) | 2015-04-23 | 2016-10-27 | Novartis Ag | Treatment of cancer using chimeric antigen receptor and protein kinase a blocker |
| US20180207273A1 (en) | 2015-07-29 | 2018-07-26 | Novartis Ag | Combination therapies comprising antibody molecules to tim-3 |
| EP3328418A1 (en) | 2015-07-29 | 2018-06-06 | Novartis AG | Combination therapies comprising antibody molecules to pd-1 |
| US20180340025A1 (en) | 2015-07-29 | 2018-11-29 | Novartis Ag | Combination therapies comprising antibody molecules to lag-3 |
| JP2018529753A (ja) | 2015-10-06 | 2018-10-11 | ザ・ウイスター・インステイテユート・オブ・アナトミー・アンド・バイオロジー | 転移性及び難治性癌及び腫瘍の処置のための方法及び組成物 |
| CN108495651A (zh) | 2015-12-17 | 2018-09-04 | 诺华股份有限公司 | 抗pd-1的抗体分子及其用途 |
| SG10201913163PA (en) * | 2015-12-18 | 2020-03-30 | Oncosec Medical Inc | Plasmid constructs for heterologous protein expression and methods of use |
| PT3393504T (pt) | 2015-12-22 | 2025-12-30 | Novartis Ag | Recetor de antigénio quimérico (car) de mesotelina e anticorpo contra o inibidor de pd-l1 para utilização combinada em terapia anticancerígena |
| SG11201807489PA (en) | 2016-03-04 | 2018-09-27 | Novartis Ag | Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore |
| US20190112380A1 (en) | 2016-03-29 | 2019-04-18 | University Of Southern California | Chimeric antigen receptors targeting cancer |
| WO2017173367A2 (en) | 2016-03-31 | 2017-10-05 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Extracellular vesicles, methods of making them, and methods of reducing liver uptake of extracellular vesicles |
| WO2017180587A2 (en) | 2016-04-11 | 2017-10-19 | Obsidian Therapeutics, Inc. | Regulated biocircuit systems |
| CA3024509A1 (en) | 2016-05-18 | 2017-11-23 | Modernatx, Inc. | Mrna combination therapy for the treatment of cancer |
| CN109715196A (zh) | 2016-06-13 | 2019-05-03 | 转矩医疗股份有限公司 | 用于促进免疫细胞功能的组合物和方法 |
| US11365252B2 (en) | 2016-07-20 | 2022-06-21 | University Of Utah Research Foundation | CD229 CAR T cells and methods of use thereof |
| CA3032669A1 (en) * | 2016-08-01 | 2018-02-08 | William Jia | Oncolytic herpes simplex virus vectors expressing immune system-stimulatory molecules |
| JP7467117B2 (ja) | 2016-10-07 | 2024-04-15 | ノバルティス アーゲー | 癌の治療のためのキメラ抗原受容体 |
| MX2019004327A (es) | 2016-10-14 | 2019-10-14 | Xencor Inc | Proteinas de fusion heterodimericas biespecificas que contienen proteinas de fusion fc il-15/il-15ra y fragmentos de anticuerpo pd-1. |
| MX2019004681A (es) | 2016-10-21 | 2019-10-07 | Altor Bioscience Corp | Moleculas basadas en il-15 multimericas. |
| CA3049652A1 (en) | 2017-01-10 | 2018-07-19 | Intrexon Corporation | Modulating expression of polypeptides via new gene switch expression systems |
| US11629340B2 (en) | 2017-03-03 | 2023-04-18 | Obsidian Therapeutics, Inc. | DHFR tunable protein regulation |
| AU2018227583B2 (en) | 2017-03-03 | 2023-06-01 | Obsidian Therapeutics, Inc. | CD19 compositions and methods for immunotherapy |
| US10743996B2 (en) * | 2017-03-24 | 2020-08-18 | Robert L. Bundy | Amnion putty for cartilage repair |
| JP2020517259A (ja) | 2017-04-19 | 2020-06-18 | ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム | 操作された抗原受容体を発現する免疫細胞 |
| AU2018257917B2 (en) * | 2017-04-24 | 2023-05-04 | University Of Massachusetts | Diagnosis and treatment of vitiligo |
| EP3615055A1 (en) | 2017-04-28 | 2020-03-04 | Novartis AG | Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor |
| EP3615068A1 (en) | 2017-04-28 | 2020-03-04 | Novartis AG | Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor |
| JOP20190256A1 (ar) | 2017-05-12 | 2019-10-28 | Icahn School Med Mount Sinai | فيروسات داء نيوكاسل واستخداماتها |
| CA3064375A1 (en) | 2017-05-25 | 2018-11-29 | Memorial Sloan Kettering Cancer Center | Use of the il-15/il-15ra complex in the generation of antigen-specific t cells for adoptive immunotherapy |
| IL327498A (en) | 2017-06-02 | 2026-05-01 | Juno Therapeutics Inc | Articles of manufacture and methods for treatment using adoptive cell therapy |
| CN111050545A (zh) | 2017-06-29 | 2020-04-21 | 朱诺治疗学股份有限公司 | 评估与免疫疗法相关的毒性的小鼠模型 |
| AU2018291497A1 (en) | 2017-06-30 | 2020-01-16 | Xencor, Inc. | Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15Ra and antigen binding domains |
| CA3074826A1 (en) | 2017-09-05 | 2019-03-14 | Torque Therapeutics, Inc. | Therapeutic protein compositions and methods of making and using the same |
| US11066475B2 (en) | 2017-11-01 | 2021-07-20 | Juno Therapeutics, Inc. | Chimeric antigen receptors specific for B-cell maturation antigen and encoding polynucleotides |
| WO2019089858A2 (en) | 2017-11-01 | 2019-05-09 | Juno Therapeutics, Inc. | Methods of assessing or monitoring a response to a cell therapy |
| MA49911A (fr) | 2017-11-01 | 2020-06-24 | Juno Therapeutics Inc | Anticorps et récepteurs antigéniques chimériques spécifiques de l'antigene de maturation des lymphocytes b |
| EP3724225A1 (en) | 2017-12-15 | 2020-10-21 | Juno Therapeutics, Inc. | Anti-cct5 binding molecules and methods of use thereof |
| WO2019165121A1 (en) | 2018-02-21 | 2019-08-29 | Board Of Regents, The University Of Texas System | Methods for activation and expansion of natural killer cells and uses therof |
| SG11202008261WA (en) * | 2018-03-08 | 2020-09-29 | Rubius Therapeutics Inc | Therapeutic cell systems and methods for treating cancer and infectious diseases |
| CA3094329A1 (en) * | 2018-03-19 | 2020-02-20 | Multivir Inc. | Methods and compositions comprising tumor suppressor gene therapy and cd122/cd132 agonists for the treatment of cancer |
| US11267866B2 (en) | 2018-04-04 | 2022-03-08 | Nant Holdings Ip, Llc | Immunoglobulin complex comprising interleukin-15 |
| CA3097593A1 (en) | 2018-04-18 | 2019-10-24 | Xencor, Inc. | Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof |
| CA3097625A1 (en) | 2018-04-18 | 2019-10-24 | Xencor, Inc. | Il-15/il-15ra heterodimeric fc fusion proteins and uses thereof |
| WO2019204646A1 (en) | 2018-04-18 | 2019-10-24 | Xencor, Inc. | Lag-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and lag-3 antigen binding domains |
| KR20210003814A (ko) | 2018-04-18 | 2021-01-12 | 젠코어 인코포레이티드 | IL-15/IL-15Rα Fc-융합 단백질 및 TIM-3 항원 결합 도메인을 함유하는 TIM-3 표적화 이종이량체 융합 단백질 |
| US20210047405A1 (en) | 2018-04-27 | 2021-02-18 | Novartis Ag | Car t cell therapies with enhanced efficacy |
| US20210213063A1 (en) | 2018-05-25 | 2021-07-15 | Novartis Ag | Combination therapy with chimeric antigen receptor (car) therapies |
| IL279367B2 (en) | 2018-06-13 | 2026-05-01 | Novartis Ag | BCMA chimeric antigen receptors and their uses |
| MX2020014290A (es) | 2018-06-22 | 2021-08-05 | Cugene Inc | Farmacos bioactivables a base de citoquinas y métodos de usos de los mismos. |
| CN121086085A (zh) | 2018-06-22 | 2025-12-09 | 科优基因公司 | 新型白介素-15 (il-15)融合蛋白及其用途 |
| EP3837277A4 (en) | 2018-08-17 | 2022-05-11 | Icahn School of Medicine at Mount Sinai | RECOMBINANT NEWCASTLE DISEASE VIRUSES AND THEIR USES IN THE PREVENTION OF RSV DISEASE OR HUMAN METAPNEUMOVIRUS INFECTION |
| JP7556848B2 (ja) * | 2018-09-14 | 2024-09-26 | モデルナティエックス インコーポレイテッド | ｍＲＮＡ治療薬を使用したがんを治療するための方法及び組成物 |
| US20210347851A1 (en) | 2018-09-28 | 2021-11-11 | Novartis Ag | Cd19 chimeric antigen receptor (car) and cd22 car combination therapies |
| WO2020069405A1 (en) | 2018-09-28 | 2020-04-02 | Novartis Ag | Cd22 chimeric antigen receptor (car) therapies |
| WO2020077180A1 (en) | 2018-10-11 | 2020-04-16 | Nantcell, Inc. | Treatment of immunosuppressed subjects |
| CA3116188A1 (en) | 2018-10-12 | 2020-04-16 | Xencor, Inc. | Pd-1 targeted il-15/il-15ralpha fc fusion proteins and uses in combination therapies thereof |
| US12473345B2 (en) | 2018-11-01 | 2025-11-18 | Juno Therapeutics, Inc. | Methods for treatment using chimeric antigen receptors specific for B-cell maturation antigen |
| CN119569895A (zh) | 2018-11-01 | 2025-03-07 | 朱诺治疗学股份有限公司 | G蛋白偶合受体c类5族成员d(gprc5d)特异性嵌合抗原受体 |
| BR112021009420A2 (pt) | 2018-11-16 | 2021-11-23 | Juno Therapeutics Inc | Métodos de dosagem de células t manipuladas para o tratamento de malignidades de células b |
| SG11202105422RA (en) * | 2018-11-29 | 2021-06-29 | Virogin Biotech Canada Ltd | Hsv vector with reduced neurotoxicity |
| EP4427810A3 (en) | 2018-11-30 | 2024-12-04 | Juno Therapeutics, Inc. | Methods for treatment using adoptive cell therapy |
| US11618776B2 (en) | 2018-12-20 | 2023-04-04 | Xencor, Inc. | Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15RA and NKG2D antigen binding domains |
| EA202192103A1 (ru) | 2019-01-29 | 2021-12-15 | Джуно Терапьютикс, Инк. | Антитела и химерные антигенные рецепторы, специфичные к орфанному рецептору типа рецеторной тирозинкиназы 1 (ror1) |
| WO2020198293A1 (en) * | 2019-03-25 | 2020-10-01 | Northshore University Health System | Methods and compositions comprising enhanced targeted immune gene therapy for the treatment of cancer |
| CN114651003A (zh) | 2019-09-10 | 2022-06-21 | 黑曜石疗法公司 | 用于可调调节的ca2-il15融合蛋白 |
| TW202128757A (zh) | 2019-10-11 | 2021-08-01 | 美商建南德克公司 | 具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白 |
| WO2021113644A1 (en) | 2019-12-05 | 2021-06-10 | Multivir Inc. | Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer |
| IL297147B1 (en) | 2020-04-10 | 2026-05-01 | Juno Therapeutics Inc | Methods and uses related to engineered cell therapy with a chimeric antigen receptor directed against a B-cell maturation antigen |
| KR20230107617A (ko) | 2020-11-13 | 2023-07-17 | 노파르티스 아게 | 키메라 항원 수용체(car)-발현 세포를 사용한 병용 요법 |
| US11459372B2 (en) | 2020-11-30 | 2022-10-04 | Crispr Therapeutics Ag | Gene-edited natural killer cells |
| EP4271798A1 (en) | 2020-12-30 | 2023-11-08 | CRISPR Therapeutics AG | Compositions and methods for differentiating stem cells into nk cells |
| US12234473B2 (en) | 2020-12-31 | 2025-02-25 | Immatics US, Inc. | CD8 polypeptides, compositions, and methods of using thereof |
| WO2022204267A1 (en) | 2021-03-24 | 2022-09-29 | Alkermes, Inc. | Upar antibodies and fusion proteins with the same |
| JP2025521543A (ja) | 2022-06-22 | 2025-07-10 | ジュノー セラピューティクス インコーポレイテッド | Ｃｄ１９標的ｃａｒ ｔ細胞のセカンドライン治療のための処置方法 |
| KR20250044344A (ko) | 2022-08-04 | 2025-03-31 | 노파르티스 파르마 아게 | 아토피 피부염의 치료에 유용한 il-15 저해제 |
| EP4565262A2 (en) | 2022-08-05 | 2025-06-11 | Juno Therapeutics, Inc. | Chimeric antigen receptors specific for gprc5d and bcma |
| US20260048099A1 (en) | 2022-08-16 | 2026-02-19 | The United States Of America, As Represented By The Secretary, Deparment Of Health And Human Service | Synergistic interactions for improved cancer treatment |
| US20260207667A1 (en) | 2022-12-13 | 2026-07-23 | Juno Therapeutics, Inc. | Chimeric antigen receptors specific for baff-r and cd19 and methods and uses thereof |
| WO2025019869A2 (en) * | 2023-07-20 | 2025-01-23 | The Johns Hopkins University | Cell culture medium and compositions thereof |
Family Cites Families (80)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2444713A1 (fr) | 1978-12-18 | 1980-07-18 | Pasteur Institut | Procede de production d'un adn comprenant le genome du virus de l'hepatite b et vecteur le comportant |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4675187A (en) | 1983-05-16 | 1987-06-23 | Bristol-Myers Company | BBM-1675, a new antibiotic complex |
| IL71691A (en) | 1984-04-27 | 1991-04-15 | Yeda Res & Dev | Production of interferon-ypsilon |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| JPS6297624A (ja) | 1985-10-24 | 1987-05-07 | イ−・アイ・デユポン・デ・ニモアス・アンド・カンパニ− | ガス分離法及びその膜 |
| JPS62205784A (ja) * | 1986-03-05 | 1987-09-10 | 雪印乳業株式会社 | 新しい型のプラスミノ−ゲン活性化因子の製造方法 |
| US4705540A (en) | 1986-04-17 | 1987-11-10 | E. I. Du Pont De Nemours And Company | Polyimide gas separation membranes |
| US4717394A (en) | 1986-10-27 | 1988-01-05 | E. I. Du Pont De Nemours And Company | Polyimide gas separation membranes |
| US4717393A (en) | 1986-10-27 | 1988-01-05 | E. I. Du Pont De Nemours And Company | Polyimide gas separation membranes |
| US4912197A (en) | 1987-08-14 | 1990-03-27 | E. I. Du Pont De Nemours And Company | Highly soluble clear polyimides |
| US4880442A (en) | 1987-12-22 | 1989-11-14 | E. I. Du Pont De Nemours And Company | Polyimide gas separation membranes |
| US4935490A (en) | 1988-04-13 | 1990-06-19 | E. I. Dupont De Nemours And Company | Highly soluble aromatic polyimides |
| US4863496A (en) | 1988-04-13 | 1989-09-05 | E. I. Du Pont De Nemours And Co. | Reactive posttreatment for gas separation membranes |
| US4851505A (en) | 1988-04-13 | 1989-07-25 | E. I. Du Pont De Nemours And Company | Highly soluble aromatic polyimides |
| US4838900A (en) | 1988-04-13 | 1989-06-13 | E. I. Du Pont De Nemours And Company | Polyimide gas separation membranes |
| US4961539A (en) | 1989-08-01 | 1990-10-09 | Deem K Michael | Truck-mounted pallet chipper |
| US5747334A (en) | 1990-02-15 | 1998-05-05 | The University Of North Carolina At Chapel Hill | Random peptide library |
| US6162432A (en) | 1991-10-07 | 2000-12-19 | Biogen, Inc. | Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction |
| DE4135070C1 (enExample) | 1991-10-24 | 1993-05-19 | Institut Fuer Rundfunktechnik Gmbh, 8000 Muenchen, De | |
| US6174666B1 (en) | 1992-03-27 | 2001-01-16 | The United States Of America As Represented By The Department Of Health And Human Services | Method of eliminating inhibitory/instability regions from mRNA |
| TW402639B (en) | 1992-12-03 | 2000-08-21 | Transkaryotic Therapies Inc | Protein production and protein delivery |
| US5552303A (en) | 1993-03-08 | 1996-09-03 | Immunex Corporation | DNA encoding epithelium-derived T-cell factor |
| US5574138A (en) | 1993-03-08 | 1996-11-12 | Immunex Corporation | Epithelium-derived T-cell factor |
| US5686115A (en) | 1993-12-01 | 1997-11-11 | Marine Polymer Technologies, Inc. | Poly-β-1→4-N-acetylucosamine copolymer composition with collagen |
| US6063911A (en) | 1993-12-01 | 2000-05-16 | Marine Polymer Technologies, Inc. | Methods and compositions for treatment of cell proliferative disorders |
| US5624679A (en) | 1993-12-01 | 1997-04-29 | Marine Polymer Technologies, Inc. | Methods and compositions for poly-β-1-4-N-acetylglucosamine biological barriers |
| US5622834A (en) | 1993-12-01 | 1997-04-22 | Marine Polymer Technologies, Inc. | Method of isolating poly-β-1-4-N-acetylglucosamine from microalgal culture |
| US5858350A (en) | 1993-12-01 | 1999-01-12 | Marine Polymer Technologies | Methods and compositions for poly-β-1→4-N-acetylglucosamine cell therapy system |
| JP3547163B2 (ja) * | 1994-03-17 | 2004-07-28 | 雪印乳業株式会社 | 無血清培地を用いた物質生産方法 |
| WO1995027722A1 (en) | 1994-04-06 | 1995-10-19 | Immunex Corporation | Interleukin-15 |
| US6548065B1 (en) | 1994-05-06 | 2003-04-15 | Immunex Corporation | Interleukin-15 receptors |
| US5591630A (en) | 1994-05-06 | 1997-01-07 | Immunex Corporation | Monoclonal antibodies that bind interleukin-15 receptors |
| US20020127201A1 (en) | 1994-07-01 | 2002-09-12 | Dana-Farber Cancer Institute. | Methods for inhibiting T cell responses by manipulating a common cytokine receptor gamma-chain |
| US7008624B1 (en) | 1995-02-22 | 2006-03-07 | Immunex Corporation | Antagonists of interleukin-15 |
| US5660824A (en) | 1995-05-24 | 1997-08-26 | Grabstein; Kenneth H. | Muscle trophic factor |
| DE19608813C2 (de) | 1996-03-07 | 1998-07-02 | Angewandte Gentechnologie Syst | Konjugat zur Beeinflussung von Wechselwirkungen zwischen Proteinen |
| US6451308B1 (en) | 1996-04-26 | 2002-09-17 | Beth Israel Deaconess Medical Center | Antagonists of interleukin-15 |
| JP2001502521A (ja) | 1996-04-26 | 2001-02-27 | ベス イスラエル デアコネス メディカル センター | インターロイキン―１５の拮抗剤 |
| EP0971728B1 (en) | 1997-02-21 | 2002-12-11 | Vlaams Interuniversitair Instituut voor Biotechnologie vzw. | Use of interleukin-15 |
| TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
| US6787132B1 (en) | 1997-12-04 | 2004-09-07 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Combined chemo-immunotherapy with liposomal drugs and cytokines |
| US20040170604A1 (en) | 1998-07-06 | 2004-09-02 | Tosoh Corporation | IL-6 receptor IL-6 direct fusion protein |
| JP2003525061A (ja) | 2000-03-01 | 2003-08-26 | メディミューン，インコーポレイテッド | 高効力組換え抗体およびその産生法 |
| US6569681B1 (en) | 2000-03-14 | 2003-05-27 | Transkaryotic Therapies, Inc. | Methods of improving homologous recombination |
| WO2001080889A1 (en) | 2000-04-26 | 2001-11-01 | National Jewish Medical And Research Center | Product and process for regulation of t cell responses |
| MXPA03002278A (es) | 2000-09-14 | 2004-12-03 | Beth Israel Hospital | Modulacion de respuestas de la celula t mediadas por il-2 e il-15. |
| US6818216B2 (en) | 2000-11-28 | 2004-11-16 | Medimmune, Inc. | Anti-RSV antibodies |
| PE20020574A1 (es) | 2000-12-06 | 2002-07-02 | Wyeth Corp | Anticuerpos humanizados que reconocen el peptido amiloideo beta |
| US7041657B2 (en) | 2001-02-12 | 2006-05-09 | Marine Polymer Technologies Inc. | Compositions and methods for modulation of vascular structure and/or function |
| US7638604B2 (en) | 2001-02-23 | 2009-12-29 | Genetics Institute, Llc | Monoclonal antibodies against interleukin-22 |
| US20030044406A1 (en) | 2001-03-02 | 2003-03-06 | Christine Dingivan | Methods of preventing or treating inflammatory or autoimmune disorders by administering CD2 antagonists in combination with other prophylactic or therapeutic agents |
| GB0209893D0 (en) * | 2002-04-30 | 2002-06-05 | Molmed Spa | Conjugate |
| EP1575509B1 (en) | 2002-05-10 | 2011-10-26 | Purdue Research Foundation | Epha2 agonistic monoclonal antibodies and methods of use thereof |
| EP1519956B1 (en) | 2002-05-10 | 2011-09-21 | Medimmune, Inc. | Epha2 monoclonal antibodies and methods of use thereof |
| US8663622B2 (en) | 2002-12-16 | 2014-03-04 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Recombinant vaccine viruses expressing IL-15 and methods using the same |
| DE10260805A1 (de) | 2002-12-23 | 2004-07-22 | Geneart Gmbh | Verfahren und Vorrichtung zum Optimieren einer Nucleotidsequenz zur Expression eines Proteins |
| US9068234B2 (en) | 2003-01-21 | 2015-06-30 | Ptc Therapeutics, Inc. | Methods and agents for screening for compounds capable of modulating gene expression |
| AU2004214932B2 (en) | 2003-02-24 | 2009-12-03 | Marine Polymer Technologies, Inc. | Cell-polymer fiber compositions and use thereof |
| WO2005023289A1 (ja) | 2003-09-08 | 2005-03-17 | Intellectual Property Consulting Incorporated | 慢性ｃ型肝炎を治療するための医薬組成物 |
| US7435596B2 (en) | 2004-11-04 | 2008-10-14 | St. Jude Children's Research Hospital, Inc. | Modified cell line and method for expansion of NK cell |
| ES2367027T3 (es) | 2004-02-27 | 2011-10-27 | Inserm (Institut National De La Santé Et De La Recherche Medicale) | Sitio de unión de la il-15 para il-15ralfa y mutantes específicos de il-15 que tienen actividad agonista/antagonista. |
| US20060057680A1 (en) | 2004-08-11 | 2006-03-16 | Zheng Xin X | Mutant interleukin-15 polypeptides |
| US20060104945A1 (en) * | 2004-10-05 | 2006-05-18 | Choi Yong S | Enhancement of B cell proliferation by IL-15 |
| EP1824964A4 (en) | 2004-11-19 | 2009-04-01 | Biogen Idec Inc | METHODS FOR PRODUCING MAMMAL CELLS |
| WO2006063301A1 (en) * | 2004-12-10 | 2006-06-15 | Maxcyte, Inc. | Genetically modified tumor cells as cancer vaccines |
| BRPI0607351A2 (pt) | 2005-02-15 | 2009-09-01 | Novartis Vaccines & Diagnostic | métodos para tratamento de linfomas empregando uma combinação de agente quimioterapêutico e il-2 e opcionalmente um anticorpo anti-cd20 |
| US20060257361A1 (en) | 2005-04-12 | 2006-11-16 | Government Of The Us, As Represented By The Secretary, Department Of Health And Human Services | Novel form of interleukin-15, Fc-IL-15, and methods of use |
| WO2007001677A2 (en) | 2005-05-17 | 2007-01-04 | University Of Connecticut | Compositions and methods for immunomodulation in an organism |
| EP1777294A1 (en) | 2005-10-20 | 2007-04-25 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins |
| WO2007070488A2 (en) | 2005-12-12 | 2007-06-21 | The Cbr Institute For Biomedical Research, Inc. | Integrin alpha l i domain mutants with increased binding affinity |
| US20070160578A1 (en) | 2005-12-14 | 2007-07-12 | The Gov. Of The Usa As Represented By The Secretary Of The Dep. Of Health And Human Services | Expansion of natural killer and CD8 T-cells with IL-15R/ligand activator complexes |
| EP2366787B1 (en) | 2006-01-13 | 2019-12-11 | The Government Of The U.S.A, As Represented By The Secretary, Dept. Of Health And Human Services | Codon optimized IL-15 and IL-15R-Alpha genes for expression in mammalian cells |
| AU2007214426A1 (en) | 2006-02-16 | 2007-08-23 | Nascent Biologics, Inc. | Methods for improving immune function and methods for prevention or treatment of disease in a mammalian subject |
| US8586055B2 (en) | 2007-01-12 | 2013-11-19 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | DNA immunization protocols |
| EP2388266B1 (en) | 2007-05-11 | 2014-04-23 | Altor BioScience Corporation | Fusion molecules and IL-15 variants |
| EP2173378B1 (en) | 2007-06-27 | 2014-03-19 | Admune Therapeutics LLC | Complexes of il-15 and il-15ralpha and uses thereof |
| WO2011020047A1 (en) | 2009-08-14 | 2011-02-17 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Use of il-15 to increase thymic output and to treat lymphopenia |
| JP6251570B2 (ja) | 2010-09-21 | 2017-12-20 | アルター・バイオサイエンス・コーポレーション | 多量体ｉｌ−１５可溶性融合分子並びにその製造及び使用方法 |
| EP2537933A1 (en) | 2011-06-24 | 2012-12-26 | Institut National de la Santé et de la Recherche Médicale (INSERM) | An IL-15 and IL-15Ralpha sushi domain based immunocytokines |
-
2008
- 2008-06-27 EP EP08779855.9A patent/EP2173378B1/en active Active
- 2008-06-27 EP EP13195499.2A patent/EP2724728B1/en not_active Revoked
- 2008-06-27 CA CA2691785A patent/CA2691785C/en active Active
- 2008-06-27 ES ES08779855.9T patent/ES2466916T3/es active Active
- 2008-06-27 WO PCT/US2008/008084 patent/WO2009002562A2/en not_active Ceased
- 2008-06-27 ES ES13195499T patent/ES2716476T3/es active Active
- 2008-06-27 EP EP13195495.0A patent/EP2724727A1/en not_active Withdrawn
- 2008-06-27 AU AU2008269032A patent/AU2008269032B2/en active Active
- 2008-06-27 NZ NZ61625408A patent/NZ616254A/en unknown
- 2008-06-27 NZ NZ703668A patent/NZ703668A/en unknown
- 2008-06-27 NZ NZ582330A patent/NZ582330A/en unknown
- 2008-06-27 NZ NZ599338A patent/NZ599338A/xx unknown
- 2008-06-27 JP JP2010514839A patent/JP2010531878A/ja active Pending
- 2008-06-27 US US12/666,052 patent/US9931377B2/en active Active
- 2008-06-27 DK DK08779855.9T patent/DK2173378T3/da active
-
2009
- 2009-12-27 IL IL202997A patent/IL202997A/en active IP Right Grant
-
2014
- 2014-01-08 JP JP2014001373A patent/JP2014114294A/ja active Pending
- 2014-10-29 HK HK14110832.5A patent/HK1198421A1/en unknown
-
2015
- 2015-06-08 JP JP2015115431A patent/JP2015212270A/ja active Pending
-
2016
- 2016-11-22 JP JP2016226503A patent/JP2017079745A/ja not_active Withdrawn
-
2017
- 2017-02-03 US US15/424,621 patent/US10265382B2/en active Active
-
2018
- 2018-12-27 JP JP2018245439A patent/JP2019088288A/ja not_active Withdrawn
-
2019
- 2019-03-04 US US16/291,561 patent/US11110150B2/en active Active
-
2021
- 2021-05-21 JP JP2021086283A patent/JP2021152017A/ja active Pending
-
2022
- 2022-10-28 JP JP2022172896A patent/JP2023015158A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Gong et al. | In situ PEGylation of CAR T cells alleviates cytokine release syndrome and neurotoxicity | |
| RU2487723C2 (ru) | Химерные и гуманизированные антитела к cd44, которые опосредствуют цитотоксичность в отношении раковых клеток | |
| Huang et al. | CAR-macrophage: breaking new ground in cellular immunotherapy | |
| ATE481483T1 (de) | Verfahren zur herstellung eines rekombinanten polyklonalen proteins | |
| WO2009014708A3 (en) | Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof | |
| EA201590631A1 (ru) | Антигенсвязывающие белки, способные связывать тимусный стромальный лимфопоэтин | |
| MX2011006422A (es) | Autoanticuerpos humanos anti-alfa-sinucleina. | |
| HRP20211582T1 (hr) | Protutijela specifična za tgf-beta | |
| NZ717429A (en) | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly | |
| EP4289944A3 (en) | Method for preparing genetically-modified t cells which express chimeric antigen receptor | |
| MX2010008570A (es) | Anticuerpos alfa5-beta1 y sus usos. | |
| RU2012143793A (ru) | Биспецифические двухвалентные антитела анти-vegf/анти-ang-2 | |
| JP2011504099A5 (enExample) | ||
| Xia et al. | Engineering a HER2-CAR-NK cell secreting soluble programmed cell death protein with superior antitumor efficacy | |
| WO2007067744A3 (en) | Method for assembling a polymer-biologic delivery composition | |
| Xiao et al. | Natural killer cells: a promising kit in the adoptive cell therapy toolbox | |
| Gomzikova et al. | Mesenchymal stem cell derived biocompatible membrane vesicles demonstrate immunomodulatory activity inhibiting activation and proliferation of human mononuclear cells | |
| Ren et al. | Translational models in glioma immunotherapy research | |
| Passariello et al. | Novel bi-specific immuno-modulatory tribodies potentiate T cell activation and increase anti-tumor efficacy | |
| Mishra et al. | Revolutionizing cancer treatments through stem cell-derived CAR T cells for immunotherapy: opening new horizons for the future of oncology | |
| Matarneh et al. | Regulatory T cell in kidney transplant: the future of cell therapy? | |
| Fagoonee et al. | The role of extracellular vesicles in mediating signaling in biliary epithelial cell activation and cholangiopathies | |
| Santoro et al. | Cell surface markers of mesenchymal stem cells: current knowledge and advances in characterization technologies | |
| Zhang et al. | Interleukin 21-armed EGFR-VHH-CAR-T cell therapy for the treatment of esophageal squamous cell carcinoma | |
| Hirayama et al. | Therapeutic Potential of an Anti-CD44v6 Monoclonal Antibody in Xenograft Models of Colorectal and Gastric Cancer |